As global cancer treatment rapidly evolves toward precision medicine, personalized therapy, and long-term disease control, China has emerged as one of the world’s most dynamic innovation centers in solid tumor treatment.

Supported by a massive patient population, accelerated drug approval pathways, extensive clinical trial networks, and increasingly mature multidisciplinary treatment (MDT) systems, China has reached internationally advanced—and in some areas leading—levels in the treatment of lung cancer, gastric cancer, liver cancer, breast cancer, colorectal cancer, and other major solid tumors.

For international patients facing advanced or treatment-resistant cancers, China offers not only broader access to innovative therapies and significantly lower treatment costs, but also earlier opportunities to access cutting-edge therapeutic strategies that may still be limited elsewhere.

DengYueMed serves as a professional bridge connecting international patients with China’s leading hospitals, oncology specialists, and innovative therapies. Through compliant pharmaceutical sourcing, medical coordination, and cross-border healthcare support, DengYueMed helps overseas patients efficiently and safely access high-quality cancer treatment resources in China while overcoming geographic and informational barriers.

---

China’s Solid Tumor Treatment Landscape in 2026

China has one of the world’s largest cancer patient populations. Continuous investment in oncology research, regulatory reform, and biotechnology innovation has transformed the country’s cancer treatment landscape.

Three major trends define solid tumor treatment in China during 2026.

1. CAR-T Therapy Is Expanding into Solid Tumors

For many years, CAR-T therapy was mainly used for hematologic malignancies.

China is now leading global research into applying CAR-T therapy to solid tumors.

One of the most important milestones is CT041 (Satri-cel), the world’s first Claudin18.2 (CLDN18.2)-targeted CAR-T therapy for advanced gastric and gastroesophageal junction cancer.

Clinical studies have demonstrated encouraging improvements in progression-free survival (PFS) and overall survival (OS), offering new treatment opportunities for patients whose disease has progressed after conventional therapies.

Multiple leading Chinese cancer centers continue to participate in CAR-T clinical research for solid tumors.

---

2. Rapid Expansion of Immunotherapy and ADC Therapy

China has approved more than twenty PD-1 and PD-L1 inhibitors.

These medicines are now widely combined with:

• Chemotherapy
• Anti-angiogenic therapy
• Targeted therapy
• Radiotherapy

Antibody-drug conjugates (ADCs) have also become one of the fastest-growing treatment areas.

Current research focuses on biomarkers including:

• HER2
• TROP2
• CLDN18.2
• Nectin-4

These therapies are expanding treatment options for patients with:

• Breast cancer
• Lung cancer
• Gastric cancer
• Urothelial carcinoma
• Other advanced solid tumors

---

3. Precision Medicine Continues to Advance

Comprehensive molecular testing has become increasingly routine before treatment decisions.

Common diagnostic techniques include:

• Next-Generation Sequencing (NGS)
• Liquid biopsy
• PD-L1 testing
• MSI-H / dMMR testing
• HER2 testing
• CLDN18.2 biomarker analysis

These tests help physicians identify patients who may benefit from personalized targeted therapies or immunotherapy.

China has also expanded access to minimally invasive interventional oncology, including:

• TACE
• Radiofrequency ablation
• Microwave ablation
• Radioactive seed implantation
• Proton therapy
• Heavy ion therapy

---

Why More International Patients Are Choosing China

Several factors continue attracting international cancer patients.

Faster Access to Innovative Therapies

Many innovative medicines and treatment approaches become available in China earlier through:

• Clinical trials
• Expanded access programs
• Accelerated NMPA approvals

---

Cost Advantages

Many advanced cancer treatments cost substantially less than comparable treatment in Western countries.

Patients may find cost advantages in:

• CAR-T therapy
• Long-term immunotherapy
• Targeted therapy
• Hospitalization
• Supportive care

---

Extensive Clinical Experience

China treats one of the world’s largest numbers of cancer patients each year.

Leading oncology centers therefore accumulate extensive experience in managing:

• Rare tumor types
• Advanced cancers
• Complex multidisciplinary cases

---

Mature MDT Care

Many leading hospitals operate comprehensive MDT systems integrating:

• Medical oncology
• Surgical oncology
• Radiation oncology
• Imaging
• Pathology
• Rehabilitation
• Nutrition

This collaborative approach helps develop individualized treatment strategies.

---

Leading Cancer Hospitals in China

Several hospitals are widely recognized for solid tumor treatment.

National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (Beijing)

Areas of expertise include:

• Lung cancer
• Gastric cancer
• Breast cancer
• Esophageal cancer
• Precision oncology
• Radiation oncology

---

Peking University Cancer Hospital (Beijing)

Internationally recognized for:

• Gastrointestinal cancers
• Precision oncology
• Cellular therapy
• CLDN18.2 CAR-T research
• Immunotherapy

---

Fudan University Shanghai Cancer Center

Major specialties include:

• Breast cancer
• Colorectal cancer
• Pancreatic cancer
• Head and neck tumors

The hospital has extensive experience in minimally invasive surgery and translational research.

---

Sun Yat-sen University Cancer Center (Guangzhou)

Leading specialties include:

• Liver cancer
• Lung cancer
• Nasopharyngeal carcinoma
• Colorectal cancer

The hospital is particularly experienced in liver cancer interventions and multidisciplinary treatment.

---

Current Treatment Status of Major Solid Tumors

Non-Small Cell Lung Cancer (NSCLC)

Modern treatment increasingly combines:

• EGFR targeted therapy
• ALK inhibitors
• KRAS inhibitors
• Immunotherapy

---

Gastric Cancer

Emerging treatment options include:

• CLDN18.2 targeted therapy
• HER2-directed therapy
• CAR-T clinical programs

---

Liver Cancer

Treatment strategies increasingly integrate:

• Targeted therapy
• Immunotherapy
• TACE
• Ablation
• Surgical conversion therapy

---

Breast Cancer

Patients now have broader access to:

• ADC therapies
• CDK4/6 inhibitors
• PARP inhibitors
• HER2-targeted therapy

---

Colorectal Cancer

Important advances include:

• MSI-H immunotherapy
• Precision targeted therapy
• Molecular-guided treatment

---

Practical Guidance for International Patients

Before traveling to China, patients are encouraged to prepare:

• Pathology reports
• Imaging studies
• Previous treatment records
• Genomic testing reports
• Current medication history

Choosing an appropriate hospital should be based on:

• Cancer type
• Disease stage
• Molecular biomarkers
• Previous treatments
• Individual treatment goals

All treatment decisions should ultimately be made by qualified oncology specialists following a comprehensive clinical evaluation.

---

How Med Supports International Patients

DengYueMed helps overseas patients connect with China’s leading oncology resources through services including:

• Medical record pre-assessment
• Hospital matching
• Specialist consultation coordination
• Medical document translation
• Treatment planning support
• Cross-border medical coordination

Our goal is to help international patients better understand treatment options available in China while facilitating efficient communication with hospitals and healthcare professionals.

---

Conclusion

China has become one of the world’s fastest-growing centers for advanced solid tumor treatment.

Innovations in CAR-T therapy, immunotherapy, precision medicine, proton and heavy ion therapy, minimally invasive oncology, and targeted therapies continue expanding treatment opportunities for patients worldwide.

For international patients, China offers access to experienced multidisciplinary teams, rapidly developing innovative therapies, and comprehensive cancer care at competitive costs.

DengYueMed remains committed to supporting international patients by providing reliable medical information and facilitating connections with hospitals, physicians, and treatment resources across China.

As global oncology continues to evolve, responsible international collaboration will play an increasingly important role in improving access to advanced cancer care.

---

Disclaimer

This article is intended for educational and informational purposes only.

It does not constitute medical advice, diagnosis, or treatment recommendations.

Treatment decisions should always be made in consultation with qualified healthcare professionals based on each patient’s individual medical condition.

Treatment availability, regulatory approvals, and eligibility criteria may vary between hospitals and regions.

---

About DengYueMed

DengYueMed is a cross-border medical collaboration platform dedicated to helping international patients connect with leading hospitals, oncology specialists, and innovative therapies in China.

Our services include:

• Medical information support
• Hospital referral coordination
• Specialist consultation assistance
• Medical record organization
• Cross-border treatment coordination

We are committed to helping patients access reliable medical information and make informed healthcare decisions.